Navigation Links
Partnership Formed to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments
Date:5/10/2013

SAN DIEGO, May 10, 2013 /PRNewswire-USNewswire/ -- The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers (Denovo) have announced a partnership to explore using Denovo's technology to identify potential responder groups for drugs being studied in ALS patients.  This personalized medicine approach may accelerate drug development in ALS and other life-threatening disorders.

The partnership will integrate Denovo's pharmacogenomic technology into the analysis of biological samples obtained from expanded access programs (EAP's) that ALS-ETF sponsors.  By identifying genomic biomarkers that correlate with patients' responsiveness to treatment, the partners seek to identify appropriate patient subsets for the conduct of subsequent trials. 

"This exciting relationship with Denovo Biomarkers may accelerate the development of drugs for ALS and may help us provide useful information for patients and physicians," said Jess Rabourn , Managing Director of ALS-ETF.  Dr. Wen Luo , Chief Scientific Officer for Denovo Biomarkers, noted, "This partnership leverages the mission of ALS-ETF and the broad utility of our platform. We hope that our combined efforts will lead to better, more targeted treatments for ALS."

About The ALS Emergency Treatment Fund (ALS-ETF)

The ALS Emergency Treatment Fund, headquartered in San Francisco, is a nonprofit company created to provide near-term treatment options to sufferers of amyotrophic lateral sclerosis (ALS), a fatal disease that compromises patients' ability to move, speak, swallow and breathe.  ALS-ETF, under license from participating pharmaceutical companies, and as authorized by FDA, implements Expanded Access treatment programs (EAP's) for investigational products in development for ALS. ALS-ETF will also leverage data obtained via EAP's to add scientific value to the clinical development of each compound. By observing a broader spectrum of patients than those typically in registration trials, EAP's may illuminate how subgroups of ALS patients respond to treatment, at different stages of disease progression.  Visit www.alsetf.org.

About Denovo Biomarkers

Denovo Biomarkers, based in San Diego, is a privately-held biotechnology company providing novel biomarker approaches to personalized drug development. The company offers the industry's first platform and algorithm for de novo genomic biomarker discovery using archived clinical samples. This technology is especially useful for compounds with suboptimal aggregate but heterogeneous late-stage trial results.  By identifying biomarkers correlated with patients' response to drug candidates retrospectively, Denovo enables biopharmaceutical manufacturers to design follow-on clinical trials in targeted patient populations while optimizing efficacy, safety and tolerability. Visit www.denovobiomarkers.com.

Contact: 
Jess Rabourn , The ALS Emergency Treatment Fund, jess.rabourn@alsetf.org, (415) 637-4774 
Michael Haller , Denovo Biomarkers, mhaller@denovobiomarkers.com, (858) 876-4012

 


'/>"/>
SOURCE The ALS Emergency Treatment Fund
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
2. VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
3. Bayer Partnership Delivers Industry-First Dose Management Offering
4. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
5. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
6. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
7. Scotland-based Innova Partnerships Ltd. Opens Boston Office
8. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
9. Partnership Aims to Prevent Students from Misusing Prescription Drugs
10. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
11. Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016  ivWatch, a medical devices company, is ... Award granted by Governor Terry McAuliffe,s office. ivWatch ... February 25th at an event to be held at the ... award honors professionals and business that have made significant contributions ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> Research ...
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier Medical ... or the "Company"), which develops, markets and sells ... China and international markets, ... which aims to concentrate the Company,s resources to ... respiratory business and to focus more on its ...
Breaking Medicine Technology:
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... With ... and easily add warm color grades to their footage. A LUT is a Lookup ... pixel's color to the corresponding color indicated by the table. By manipulating each pixel, ...
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on April 7, ... Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care ... with Parkinson’s disease and is the architect of this informative event to raise awareness ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President ... have signed a joint enrollment and degree completion agreement. The agreement, which ... baccalaureate degrees at FHU|Dickson. , The agreement allows students to be jointly ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... independent PROSHRED franchises from across the country gathered at the La Valencia Hotel ... top performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking ...
Breaking Medicine News(10 mins):